We would love to hear your thoughts about our site and services, please take our survey here.
Have you just given birth to a rumor :)
According to a set of trial data released by the German vaccine commission, just two of 660 trial participants over the age of 65 got Covid-19 — one in the vaccinated and one in the control group — which is far below the number needed to draw statistical conclusions. That set of trial data showed an overall efficacy of 70.4 per cent.
Germany’s move could raise questions in the UK, where the vaccine is approved for all persons aged 18 and over. When the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), approved it for emergency use last month, health authorities acknowledged there was a small amount of data on older populations, but that more results would become available this year.
The MHRA did not immediately respond to a request for comment.
Thought Novacut would get in. Spin off of cambridge got the nod
https://drw-ltd.com/drw-media/news-articles/rapid-covid-19-diagnostic-test-developed-by-cambridge-team-to-be-introduced-in-hospitals.html
https://www.cuh.nhs.uk/news/rapid-coronavirus-test-speeds-access-urgent-care/
Colchicine is not a competitor for SNG-001. The mechanism of its action is completely different to the SNG-001. It may find a place WITH Synterferon.
Link for a good BMJ article which outlines the mechanism if action if you follow a bit of medicine. SNG 001 is needed in phase 1 and Colchicine in Phase 3
COVID-19 progression can be divided into three distinct phases (figure 1) including: (1) early infection phase, wherein the virus infiltrates host cells in the lung parenchyma; (2) pulmonary phase, in which viral propagation causes lung tissue injury as the host immune response is activated and (3) the inflammatory cascade, which is triggered by pathogen-associated molecular patterns (ie, viral RNA) and damage-associated molecular patterns (DAMPs, ie, cellular debris released during pyroptosis) exposed during active viral replication and release. This third phase of the inflammatory cascade may occur even as viral titers are falling and is comprised of components targeted by colchicine (activation of the inflammasome that drives the cytokine storm, activation of neutrophils and the neutrophil/thrombosis interface)2 (figure 2).
https://ard.bmj.com/content/early/2020/12/08/annrheumdis-2020-219174
No news where published etc or details of patient group. Colchicine oral
Quebec researchers say they have found an effective drug to fight COVID-19
https://montreal.ctvnews.ca/quebec-researchers-say-they-have-found-an-effective-drug-to-fight-covid-19-1.5279310
Based on original registration, study completion of February 17, which is 28 days after first dosing of last patient they have reached their goal if you look at it in a realistic view.
Look at full details towards half way of the publication including trial design phase 2.
https://clinicaltrials.gov/ct2/show/NCT04385095
Most of you are not aware of how trials are done not being in the medical feild of work and keep whinging as if it is a cakewalk setting up big phase 3 trial of this magnitude
Most dont understand
1. How difficult it is to set up trials, get ethical approval in different countries, write up trial data info, passing it through regulators, corrections/ additional data added. Medicolegal input included. Multicountry vital to see effectiveness across different races for use worldwide then.
2. Getting clinicians of various involved hospitals on board and some taking Lead on it to take interest to start trial. Putting in place all trial material including drugs stored in local hospitals, setting up trial coordinators to help with trials or managing adverse events.
3. Extrapolate this to a very small company with limited resources trying to work with FDA and in 20 countries with each having different languages and regulatory requirements. Changes in trial arm requires changes from statistical experts, reprinting of trial paper material, guidelines etc.
Yes so called new investors who came hunting for gold have entered the casino and impatient to strike rich at the throw of a dice. If bought at 35p or 70p people are relaxed and those who got in at 200p or higher are stressed understandably.
The synairgen team are top professionals and kudos for pulling off phase 2 that fast. They are not delaying anything on their own. Regulatory hurdles are easy to overcome for big pharmas as they have well oiled machinety/teams doing trials across the world and have close connections with regulatory bodies to move things faster.
Writing up a paper is a complex work as peers from a journal ask clarification for additional info many times before accepting it. Most have missed the point that phase 2 actually had 38 and 36 patients for comparison after the dropouts. This is small number for any regulatory body to give EUA. The results even though very good are debatable. Again synairgen does not have clout of big pharma to influence regulatory bodies.
So patience and it will pay or else invest in TESLA or Bitcoin ??
Watch the video.
https://youtu.be/OumhrE6JV3A
Published on 13 Dec 2020
A major leak containing a register with the details of nearly two million CCP members has occurred – exposing members who are now working all over the world, while also lifting the lid on how the party operates under Xi Jinping, says Sharri Markson. Ms Markson said the leak is a register with the details of Communist Party members, including their names, party position, birthday, national ID number and ethnicity. “It is believed to be the first leak of its kind in the world,” the Sky News host said. “What's amazing about this database is not just that it exposes people who are members of the communist party, and who are now living and working all over the world, from Australia to the US to the UK,” Ms Markson said. “But it's amazing because it lifts the lid on how the party operates under President and Chairman Xi Jinping”. Ms Markson said the leak demonstrates party branches are embedded in some of the world’s biggest companies and even inside government agencies. “Communist party branches have been set up inside western companies, allowing the infiltration of those companies by CCP members - who, if called on, are answerable directly to the communist party, to the Chairman, the president himself,” she said. “Along with the personal identifying details of 1.95 million communist party members, mostly from Shanghai, there are also the details of 79,000 communist party branches, many of them inside companies”. Ms Markson said the leak is a significant security breach likely to embarrass Xi Jinping. “It is also going to embarrass some global companies who appear to have no plan in place to protect their intellectual property from theft. From economic espionage,” she said. Ms Markson said the data was extracted from a Shanghai server by Chinese dissidents, whistleblowers, in April 2016, who have been using it for counter-intelligence purposes. “It was then leaked in mid-September to the newly-formed international bi-partisan group, the Inter-Parliamentary Alliance on China - and that group is made up of 150 legislators around the world. “It was then provided to an international consortium of four media organisations, The Australian, The Sunday Mail in the UK, De Standaard in Belgium and a Swedish editor, to analyse over the past two months, and that's what we've done". Ms Markson said it, “is worth noting that there's no suggestion that these members have committed espionage - but the concern is over whether Australia or these companies knew of the CCP members and if so have any steps been taken to protect their data and people”.
Delighted that many here who saw Glen plummet to 115p are better off with the spectacular recovery in copper price and Glen. A big Woosh of Glen as Ken phrases it. A vertical take off for 100p as of now. Happy fellow investors are making money or recovering losses.
Many bought and sold SNG for a profit I see. Well done for taking the punt. Like I have all along said 2 companies on AIM with potential were Novacyt and SNG. SNG especially with variants rising a big worry, its therapeutic route of action via interferon beta which will be active against any covid variant is immense. A minnow UK company trying to make it big with no support from BOJo to get FDA interested is really an achievement.
FDA has awarded SNG001 Fast Track status, enhancing the ability of Synairgen to interact with the FDA and shortening review timelines. So watch out in 2 months as preliminary data of p3 are analysed with home trials being completed with rising covid sadly next 2 months. Novacyt has big sales figures and some contracts due to take it back to 1200p. Yes next few days you can trade both.
Day hopefully you will soon to get the pfizerBiontech vaccine. Got mine a few days ago as frontline clinician with high covid age. Not all docs have got it and nurses are still waiting and more are going off due to covid infections worryingly leaving fewer and fewer on the wards across many trusts. We need to see how effective vaccine will be with new variants rapid changes. So still concerned managing emergencies. Right mess we are in due to the CCP virus. Bloody communist party and their pride, secrecy to blame.
Take care all. Dont post often if I dont have much to add. Ken hope you keeping well. Billy hope your Mrs is not at breaking point with nurse shortage rising.
Looks like this virus will become covid-20 soon.
Did current variant come from South Africa ?
New ‘worrying’ Covid strain found in South Africa is ‘more severe among young adults'
https://www.express.co.uk/news/world/1374779/covid-strain-latest-new-coronavirus-variant-south-africa-young-adults/amp
Closest to next positive news to take this up is the home trial completion. About 60 patients away 2 weeks ago. Results of that will hasten the EUA rather than P3
Currently being distributed for twice weekly testing in NHS. Innova had the first mover LFT advantage perhaps.
This might be one of the reasons for the drop in AVCT yesterday and last 2 days for Novacyt.
Number of PCR tests in NHS hospital staff will go down with LFT competing.
Pete, Aether regarding Synairgen you have to remember the phase 3 trials have just started. Medical Health Regulation Authority in UK have put SNG-001 in the priority treatment research with National Institute of health research recruiting patients. Phase 3 trial interim data world wide will be in January with case rising now. In summer not enough cases meeting criteria for inclusion for their home trials and not sadly with rise in cases recruitment will be faster.
Patience is the key, it’s taken big pharma 6 to 8 months and billions themselves and governments pumping money to get here with vaccines. Synairgen is a small company doing it methodically with input from FDA trials in USA.
Biotech and medical stocks are tough at times to hold. When results go their way they move fast. Any stock if you invest you need to look at 6 to 12 months horizon minimal outside of your day or short term trade pot.
4 Mondays we have had Vaccine news hunting sentiments of covid related diagnostic and therapeutic stocks. Novacyt dropped from 190 to 65p, 450p to 210p and look where it is ( there is sales there). Similarly with synairgen. Big institutions are invested in synairgen at 200p and 175p placement.
People who had bought Glen at 350p saw it crash down to 125p, IAG from rights adjusted 290p to 90p, Greg's from 2300p to 1200p, Fresnillo from 1200p to 580p . Sometimes if you have conviction in the stock and done your research then need to stop looking at daily price movements. If anyone wants to play safe without doing research there are good funds which offer stocks like BIOG, JII, FCSS etc. Despite research private investors dont get to know of scandals or poor business decisions and many stocks fall and nothing one can do then.
Investment in AIM shares has risks with rewards when it comes to good companies and there are a good few over the years. Boards give an overview.
A good few wise men here stay away from AIM. Each to his own.
What a big upside wave from 155 at start of October for Glen to touch 200 today. Great reversal for Glencorians indeed QZ after 9 to 10 months of pain. Still a way to go for those who bought at 300 to 350p levels.
https://www.bbc.co.uk/news/explainers-54880084
Good simple article
Well analysed Day for Pete. Hope you keeping well.
We rejoiced for half an hour when we heard the news in hospital with rising cases and colleagues getting infected in our hospital. Looking at news closely we were a bit disheartened because full details of age groups especially over 60s efficacy etc not revealed. Not peer reviewed. Minus 80 degree chain. 40 million booked for UK with limited production capacity before spring with 2 doses 3 weeks apart will make it like war time rationing or lottery.
Pete re Novacyt they are having enough contracts like already explained. Even with vaccine testing needed for next year and more so for next 3 months with moonshot goal.
Boris for first time stated the truth today that the vaccine is not going to help us in the near future. Biden put out similar message.
Synerairgen is covid and COPD play. Treatment is required world wide even if vaccine is effective especially elderly as vaccine may not be that helpful. Vaccine with effective therapeutic is the way with mutations occurring.
I have been through big drops in Nova and Synairgen by 50% in past but these 2 companies have strong fundamentals and risen with proper news. Synaigen have £94 million in bank and phase 3 starting. I have enough profit cushion to relax and sympathise with your well founded worry. Peer review article of synairgen will be next booster.
Nursing home trial data and next NHS contract will take Nova up.
Imagine you bought Glen or IAG or Rolls Royce in February you would be holding them patiently.
Risk is there in AIM stocks and hence many wise men on this board don't want to venture there and play safe in FTSE 250 or 100 stocks
Pete saw your message on Nova board.
Pete I am back in with big holding in Nova and much bigger in Synairgen. Have Avacta, Hemo, TILS.
Your 981p entry is still good as Nova should breach 1300p in few weeks. Did not think I would say this in October when I sold at 560p area for a 30 to 40% profit across ISA accounts then ( no regrets)
In many big hospitals they are having a tough time keeping up with demand to do the tests locally as staff are getting infected faster with this second surge and demands for daily tests are surging. Winterplex demand will be high from December through to March.
Novacyt has planned business growth with manufacturing , distribution, sales partners worldwide. Gem of a UK company with UK heads leading.
Synairgen have published the 4 year old study with Astra Zeneca of the stopped Astma study 2 weeks ago in resp investigative journal. Mainly to highlight safety of drug and use it for cross reference for the forthcoming peer reviewed article in Lancet respiratory probably. Will make it more popular in medical circles and aid in sales of Managed Access Program of SNG001 in hospitals to treat. Both articles will assist use of medication even midway through P3 trial as safety already shown in 2 peer reviewed randomised studies.
“We will need to see some serious concrete plans, and quickly, if we are not to suspect that the prime minister’s statement was purely about news management.”
Appointments challenged
The government is also facing criticism over how it appoints people to key public sector roles during the pandemic. In a legal challenge the Good Law Project and Runnymede Trust have joined forces to put forward the case that people who were personally or politically connected with senior members of the Conservative Party have been appointed without any open competition or proper process. This was indirect discrimination (contrary to the Equality Act 2010), they said, and a breach of the public sector equality duty.
Dido Harding, appointed head of the NHS Test and Trace service and then interim head of the National Institute for Health Protection, is named in the claim. She is married to the Conservative MP John Penrose.
Mike Coupe, Gareth Williams, Ben Stimson, and Paul de Laat, all appointed to senior positions at NHS Test and Trace, have also been named. Coupe is the former chief executive officer of Sainsbury’s and a former colleague and friend of Harding from their time at Sainsbury’s, said the Good Law Project and Runnymede Trust.
Halima Begum, the trust’s director, said, “When a recruitment process is not open and fair, it discriminates against those who are not already connected to the decision makers. This has a serious detrimental impact on equality and on the diversity of the people at the top of organisations who get to call the shots. This is always important, but even more so now so many lives depend on it, and particularly as we know black and Asian people continue to be disproportionately affected by the coronavirus.
“We are calling on the government to ensure a proper process is followed and for NHS bodies to be truly representative of the people they protect.”
Covid-19: Experts question evidence behind prime minister’s promise of rapid tests
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4254 (Published 02 November 2020)
Concerns have been raised over the UK government’s claims that it will begin rolling out rapid covid-19 tests within days to whole cities to “help people discover whether or not they are infectious” and to allow them entry to certain places or events.
Announcing the second national lockdown in England on 31 October,1 Boris Johnson said that trials of rapid tests across the country in schools and hospitals had shown that they “drive down the disease.” As a result, millions of these self-administered tests, which provide results in 10-15 minutes, will now be rolled out “over the next few days and weeks.”
Johnson added that the tests would be used in an “ever growing number of situations,” including to allow partners of women giving birth to be in labour wards.
He did not name the test to be rolled out, and although three rapid antigen tests have passed Public Health England’s assessment there is little information on how they were tested or passed.2
One of these tests has since been purchased. The Telegraph reported that the government agreed a deal for 20 million of Innova’s SARS-CoV-2 antigen test kits on 19 October.3 The test involves a nose and throat swab and provides results similar to an at-home pregnancy test. However, the company’s instructions state that the test is intended only for use on people showing symptoms of covid-19 and should be used by “clinical laboratory personnel specifically instructed and trained in the techniques of in vitro diagnostic procedures.” As such, this test would not be suitable for testing asymptomatic people to allow access, as Johnson had claimed.
Jon Deeks, professor of biostatistics at the University of Birmingham and lead author of a recent Cochrane review of covid-19 antibody tests, has also raised concerns over Public Health England’s test assessments.4 He said, “These are initial validation studies and should not be the basis for national decision making . . . Boris [Johnson] described these as tests of whether you are infectious, but there is no mention of infectiousness in the protocol; they are assessed as tests of infection not infectiousness.”
Simon Clarke, associate professor of cellular microbiology at the University of Reading, said that Johnson’s testing announcement seemed hurried and may have been done “purely as a way to provide some sugar along with the bitter medicine of lockdown.” Nevertheless, he said that “mass rapid and effective testing and isolating of infected people really is the best way for the country to get out of this nightmare,” although the details on how this would be achieved were still “thin on the ground.”
He added, “We will need to see some serious concre
Only when the article comes out in a Journal like Lancet Respiratory Medicine or British Medical Journal, News papers and relevant medical newsletters will further highlight the study. This will push the demand for MAP and also recruitment for trial.
Not sure why even after 3 months they felt no urgency in getting the article of original research out there.